Last update 24 May 2025

Ficerafusp alfa

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
EGFR/TGFβ fusion monoclonal antibody, BCA 101
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TGF-β inhibitors(Transforming growth factor beta inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
United States
28 Jan 2025
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
Australia
28 Jan 2025
Squamous cell carcinoma of head and neck metastaticPhase 3
United States
28 Jan 2025
Squamous cell carcinoma of head and neck metastaticPhase 3
Australia
28 Jan 2025
Anal canal squamous cell carcinomaPhase 2
United States
10 Mar 2023
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Jun 2020
Advanced Malignant Solid NeoplasmPhase 1
Australia
01 Jun 2020
Advanced Malignant Solid NeoplasmPhase 1
Canada
01 Jun 2020
Colorectal CancerPhase 1
United States
01 Jun 2020
Colorectal CancerPhase 1
Australia
01 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Advanced Skin Squamous Cell Carcinoma
Second line
anti-PD-1 therapy | anti-EGFR antibodies
14
Ficerafusp alfa 1500 mg IV weekly
bfwrckujct(xaqpyvomhr) = hhtnpgavky iqejyebyel (eyohncnynw, 15.2 - 72.3)
Positive
28 Apr 2025
Phase 1
Anal canal squamous cell carcinoma
Second line | Third line
28
pwspdvrzuj(zhgutgljqk) = the most common TRAE of any grade including, acneiform dermatitis (16/28 patients; 57.1%), epistaxis (14/28 patients; 50.0%), and pruritus (13/28 patients; 46.4%). slvthbqaom (ihdqooqaqk )
Positive
27 Jan 2025
Phase 1
Anal canal squamous cell carcinoma
Second line | Third line
26
hvholsoycb(uxdqamkxyw) = ngzglgprqp klkurtbgbu (mlbycwuxhi )
Positive
23 Jan 2025
Phase 1
39
awmvbyzkcy(ixatvsmddc) = acneiform rash (76%, with majority being Grade 1/2 in severity), fatigue (43%), and hypophosphatemia (38%). ofmrzhbzmv (fwtknjocrl )
Positive
27 Jun 2024
Ficerafusp alfa (BCA101) + Pembrolizumab
(HPV-negative)
Phase 1
Squamous Cell Carcinoma of Head and Neck
First line
PD-L1 | HPV Negative
33
xqvihmwvju(zntspezbcn) = scgxynhngw nzqqzoobav (ksndseelko )
Positive
22 Oct 2023
cvsuozpwzq(gqduwaxhhk) = xcckyjpcqd ulvnkfshxn (pjnpbdmwia )
Phase 1
18
rvmdvsljen(zpuedgxepe) = kfxednthbr arlpmpvwez (hersgvahob )
Positive
26 May 2023
pawhbxeubl(qfwkburjva) = jzfarssvse xpmdxndtpt (uekrahbfdy )
Phase 1
60
pqktkoniyt(wygrkthueb) = Most common AEs attributed to BCA101 include rash (72%), fatigue (30%), pruritis (20%), and epistaxis (17%); all G2 or less nzewcyjeji (euoxvlfzsg )
Positive
10 Sep 2022
Phase 1
60
qboujjzfzh(slpdcjkzev) = Common adverse events (AEs) attributed to BCA101 include rash (70%), fatigue (23%), pruritis and epistaxis (17% each); all grade (G)2 or less uqclyavqth (emavghtwsy )
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free